Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 2 Solid Tumor 2 Meningioma 2 Carcinoma, Non-Small-Cell Lung 2 Small Cell Lung Carcinoma 1 Recurrence 1 Non-small Cell Lung Cancer Metastatic 1 Neurofibromatosis 2 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Lung Neoplasms 1 Estrogen Receptor Positive Breast Cancer 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Breast Neoplasms 1 Adenocarcinoma 1

Interventions

Etoposide 78 Carboplatin 67 Cisplatin 46 durvalumab 26 Topotecan 26 atezolizumab 20 Radiotherapy 19 Irinotecan 19 Paclitaxel 17 anlotinib 16 apatinib 15 Nivolumab 15 Drug Therapy 12 pembrolizumab 9 Platinum 9 toripalimab 8 tislelizumab 8 Gemcitabine 8 Bevacizumab 8 Temozolomide 7 Radiosurgery 7 PM 01183 7 Ipilimumab 7 Pemetrexed 6 Docetaxel 6 Albumin-Bound Paclitaxel 6 olaparib 5 amrubicin 5 Sunitinib 5 surufatinib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Small Cell Lung Carcinoma × vistusertib × Clear all

NCT03106155 2018-09-20

[SUKSES-D]

Samsung Medical Center

Phase 2 Terminated

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡